New three-drug combination treatment achieves notable responses in patients with advanced HER2-negative breast cancer

15 Feb 2024

Treatment in a recent study combined a histone deacetylase (HDAC) inhibitor - a drug that causes a chemical change to stop tumor cells from dividing - with two types of immunotherapy known as checkpoint inhibitors, which unharness the power of the immune response against cancer.